Glucovance (Metformin Hydrochloride, Glibenclamide)

Glucovance is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

• As monotherapy when metformin alone does not achieve glycemic targets.
• In combination with other oral antidiabetic agents to improve overall glucose control.
• To reduce fasting plasma glucose levels.
• To lower post‑prandial glucose excursions.
• As part of a comprehensive diabetes management plan that includes lifestyle modification.
• To assist in achieving HbA1c targets when combined therapy is required.
• To provide a convenient fixed‑dose option that may improve medication adherence.

Glucovance, like other antidiabetic agents, may cause a range of adverse effects that vary in frequency and severity.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea.
• Mild hypoglycemia, especially when meals are skipped or dosing is high.
• Weight gain or modest increase in body weight.
• Skin reactions like rash or itching.
• Transient headache or dizziness.
• Mild elevation of serum creatinine indicating temporary kidney function change.

Serious

• Severe hypoglycemia with confusion, loss of consciousness, or seizures.
• Lactic acidosis, a rare but life‑threatening condition marked by rapid breathing and muscle pain.
• Hepatotoxicity presenting as jaundice, elevated liver enzymes, or hepatic failure.
• Allergic anaphylactic reaction with swelling, breathing difficulty, or hives.

When prescribing Glucovance, clinicians should evaluate patient-specific factors and monitor for conditions that could increase the risk of adverse outcomes.

• Assess renal function before initiation and periodically thereafter, as metformin accumulation can occur in impaired kidneys.
• Use caution in patients with a history of cardiovascular disease, as sulfonylureas may affect cardiac risk.
• Monitor for signs of lactic acidosis, especially in patients with liver disease, alcohol abuse, or severe infection.
• Educate patients on recognizing hypoglycemia symptoms and the importance of consistent meal patterns.
• Consider dose adjustment or discontinuation during pregnancy or lactation, pending professional guidance.
• Review concomitant medications that may potentiate hypoglycemia or affect metformin clearance.

Glucovance can interact with several medicines, affecting blood glucose levels or the pharmacokinetics of its components.

Avoid

• Other sulfonylureas or meglitinides, which may cause additive hypoglycemia.
• Iodinated contrast agents used for imaging in patients with renal impairment, due to risk of metformin‑associated lactic acidosis.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can increase glibenclamide concentrations.

Use with caution

• Renal‑clearing drugs such as cimetidine or trimethoprim, which may raise metformin levels.
• Beta‑blockers, which can mask hypoglycemia symptoms.
• ACE inhibitors or ARBs, which may affect renal function and necessitate closer monitoring.
• Thiazide diuretics, which can increase blood glucose and require dose evaluation.